1. Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022.
- Author
-
Yanagita, Motoko, Muto, Satoru, Nishiyama, Hiroyuki, Ando, Yuichi, Hirata, Sumio, Doi, Kent, Fujiwara, Yutaka, Hanafusa, Norio, Hatta, Takahiro, Hoshino, Junichi, Ichioka, Satoko, Inoue, Takamitsu, Ishikura, Kenji, Kato, Taigo, Kitamura, Hiroshi, Kobayashi, Yusuke, Koizumi, Yuichi, Kondoh, Chihiro, Matsubara, Takeshi, and Matsubara, Kazuo
- Subjects
- *
SKIN cancer , *HYDRONEPHROSIS , *DRUG therapy , *ANTINEOPLASTIC agents , *MEDICAL libraries , *KIDNEY injuries , *MEDICAL personnel - Abstract
The article summarizes the "Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022" published by several Japanese medical societies. The guidelines provide recommendations for medical professionals on managing kidney injuries that occur during cancer pharmacotherapy. Topics covered include renal function assessment, drug-induced nephrotoxicity management, anticancer drug regimen planning, and chronic kidney disease treatment in cancer survivors. The guidelines were developed based on a literature search and consensus development process. The article also discusses specific clinical questions and recommendations related to renal function assessment, interventions for malignant ureteral obstruction, the use of immune checkpoint inhibitors in different patient populations, hydration methods during cisplatin treatments, and kidney replacement therapy for childhood cancer survivors. The evidence for these recommendations varies in strength, and further research is needed to evaluate outcomes and determine the best approaches for these treatments. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF